Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Increased sales in the B&P, Healthcare and V&S markets, the start of shipments of large projects for air traffic control applications in North America, expanded defense sales in Japan and North America, increased sales of high-value-added products, the foreign exchange effect of a weaker yen and stronger euro, fixed-cost reductions from the restructuring and streamlining of the European organisation, the absence of one-time costs related to the new technology building recorded in the same period of the previous year, and gains on sales of investment securities from the disposal of strategic shareholdings and other holdings
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥40,697 million (YoY +7.5%) |
| Operating profit | ¥1,815 million (YoY +175.1%) |
| Ordinary income | ¥2,451 million (YoY +64.3%) |
| Profit attributable to owners of the parent | ¥4,938 million (YoY +430.7%) |
| Net income per share | ¥126.47 |
| Equity ratio | End of the current fiscal period 75.6 / End of previous period 77.2 |
| Total assets | ¥221,991 million |
| Net assets | ¥167,749 million |
| Cash flows from operating activities | ¥2,454 million |
| Cash flows from investing activities | ¥8,002 million |
| Cash flows from financing activities | ¥-8,178 million |
| Cash and cash equivalents at end of period | ¥22,510 million |
| Full-year earnings forecast | Net Sales ¥85,000 million (YoY +4.5%) / Operating profit ¥3,300 million (YoY +39.5%) / Ordinary income ¥4,600 million (YoY +21.9%) / Net income ¥6,500 million (YoY -11.2%) |
| Annual Dividend Forecast | ¥110 → ¥115（+4.5%） |
| Depreciation and amortization | ¥1,462 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of investment securities / Amount ¥4,464 million, Item Gain on revision of retirement benefit plans / Amount ¥22 million / Extraordinary loss No applicable items |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 42,330,820 |
| Treasury Shares at Period-End | 4,718,304 |
| Factors Behind Changes in Business Performance | Increased sales in the B&P, Healthcare and V&S markets, the start of shipments of large projects for air traffic control applications in North America, expanded defense sales in Japan and North America, increased sales of high-value-added products, the foreign exchange effect of a weaker yen and stronger euro, fixed-cost reductions from the restructuring and streamlining of the European organisation, the absence of one-time costs related to the new technology building recorded in the same period of the previous year, and gains on sales of investment securities from the disposal of strategic shareholdings and other holdings |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales in the B&P, Healthcare and V&S markets increased. Sales growth was supported particularly by the start of shipments of large projects for air traffic control applications in North America and expanded defense sales in Japan and North America. Factors contributing to profit included increased sales of high-value-added products, the foreign exchange effect of a weaker yen and stronger euro, fixed-cost reductions from the restructuring and streamlining of the European organisation, and the absence of one-time costs related to the new technology building recorded in the same period of the previous year. The increase in interim net income attributable to owners of the parent was also supported by gains on sales of investment securities from the disposal of strategic shareholdings and other holdings.